Reverse Merger with Santersus Positions Xenetic as NET-Targeting Leader
XBIO has more than doubled off its 52-week low of $1.9 on light trading volume (0.1× avg).
Summary
Xenetic Biosciences will acquire Santersus AG in an all-stock reverse merger, with Santersus holders owning ~85% of the combined company. The new entity, Santersus Bio, Inc., will trade as SNTS and focus on NET-targeting therapies across four clinical programs.
Key Events · M&A and Partnerships · XBIO
-
Reverse Merger with Santersus AG
Xenetic will acquire all outstanding Santersus shares in exchange for newly issued Xenetic common stock. Santersus holders will own ~85% of the combined company; existing Xenetic holders ~15%.
-
Combined Pipeline of Four Programs
The merged company will advance NucleoCapture for sepsis, SLE, and liver transplantation, plus DNase for large B-cell lymphoma. Two programs hold FDA Breakthrough Device Designations.
-
Valuation and Ownership Terms
Santersus is valued at $120 million; Xenetic at $21 million plus net cash. The exchange ratio adjusts based on Xenetic's net cash at closing.
-
New Corporate Identity
The combined company will be renamed Santersus Bio, Inc. and trade on Nasdaq under ticker SNTS. Board will have 8 members: 6 from Santersus, 2 from Xenetic.
Analysis · XBIO · Life Sciences
A definitive share exchange agreement will see Xenetic Biosciences acquire privately held Santersus AG in an all-stock transaction that fundamentally reshapes the company. Under the terms, Santersus shareholders will own approximately 85% of the combined entity, while existing Xenetic holders retain roughly 15% — a reverse merger in substance. The combined company, to be renamed Santersus Bio, Inc. and trade under ticker SNTS, will focus on neutrophil extracellular trap (NET)-targeting therapies across sepsis, lupus, liver transplantation, and lymphoma. Santersus brings two FDA Breakthrough Device Designations and a $120 million valuation, while Xenetic contributes its DNase platform and a $21 million valuation plus net cash. Closing is expected in Q4 2026, subject to Xenetic stockholder approval, Nasdaq listing, and SEC effectiveness of a resale registration statement. This is a thesis-altering event: the company's pipeline, management, board composition, and corporate identity all change at closing.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 40.6% of the 409 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XBIO was trading at $4.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10M. The 52-week trading range was $1.90 to $13.93. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.